Lupus and COVID-19: What You Need to Know Webcast 2

Since the arrival of the coronavirus, lupus and the most prescribed drug used to treat it – hydroxychloroquine – have been thrust into the spotlight despite the mounting scientific evidence that the drug does not seem to improve clinical outcomes in patients with COVID-19. Talked about less is the impact and burden of COVID-19 on people with lupus. What parallels exist in the overreactive immune response seen in lupus and COVID-19? Are people with lupus more or less at risk for COVID-19? Are medications used by people with lupus more or less effective in COVID-19? Diving deep on research on behalf of the lupus community during this crisis, the Lupus Research Alliance (LRA) and Lupus Therapeutics (an affiliate of the LRA) discuss with a panel of experts actions taken to better understand these and other questions.